Category:

Release – MustGrow Announces Record Q2-2025 Results: $2.8 Million Revenue and 20.9% Gross Profit Margin for the Quarter

Posted on by aweinsoff@channelchek.com

Research News and Market Data on MGROF


 

Investor Webcast: Thursday, August 28th at 4:00pm ET / 1:00pm PT

Register/View Here: 
https://us02web.zoom.us/webinar/register/2017556244178/WN_xF4GBBCXThC3_f1GZYAkZg

Please join/register at least 5 minutes prior to the call.
Questions emailed to info@mustgrow.ca will be addressed during the Q&A portion of the webcast.

SASKATOON, Saskatchewan, Canada, August 27, 2025 – MustGrow Biologics Corp. (TSXV:MGRO) (OTC:MGROF) (FRA:0C0) (the “Company” or “MustGrow“), a leading provider of biological and regenerative agriculture solutions, is pleased to announce its operating and financial results for the three months ended June 30, 2025.  For complete details, please refer to the Q2-2025 Condensed Interim Financial Statements and associated Management’s Discussion and Analysis, available on SEDAR+: www.sedarplus.ca or on the Company’s website: www.mustgrow.ca.

 Key Financial Highlights:

  • Sales revenue of $2.8 million was recorded (including $312,832 from sales of TerraSanteTM biofertility product in the U.S.) in Q2-2025 vs. no revenue in Q2-2024
  • Gross profit of $594,718 equating to a 20.9% gross profit margin in Q2-2025 (up from 14.3% in Q1-2025)(1)
  • Cash and equivalents on hand as at June 30, 2025 was $1.8 million with inventory of $1.8 million
  • Net loss for the three-month period ended June 30, 2025 was $1.1 million and the net loss per share was $0.02 (basic) for the same period

“Our second quarter 2025 showed a gross profit margin improvement over the first quarter end March 31, 2025 resulting from sales of TerraSanteTM biofertility product in the U.S.,” stated Corey Giasson, President and CEO of MustGrow. “We sold out of our TerraSanteTM inventory in the U.S. during this second quarter, which was triple our TerraSanteTM sales in all of 2024.  The TerraSanteTM initial sales ramp-up has started and we are working on producing more product to meet the growing demand. For our Canadian sales and distribution division, NexusBioAg, Q2 and Q3 are considered the slower ‘shoulder season’ whereas Q1 and Q4 are traditionally stronger sales periods for Canadian farmers purchasing crop inputs.  Margins in this segment have picked up from the first quarter and we are looking to finish the year with a strong Q4.”

The Company continues to focus on capital allocation that generates revenue growth of both its NexusBioAg Canadian sales and distribution business and TerraSanteTM biofertility product sales in the U.S.

Notes:
1) Gross margin is a non-IFRS financial measure. This ratio expresses gross profit as a percentage of revenue for a given period. It assists in explaining the Company’s results from period to period and measuring profitability. This ratio is calculated by dividing gross profit for a period by the corresponding revenue for the period. There is no directly comparable IFRS measure.

About MustGrow

MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company’s proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers.  In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, adjuvants and foliar products.  These products are synergistically distributed alongside MustGrow’s wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers.  Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow’s wholly-owned proprietary products and technologies.  The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio of approximately 109 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg.  MustGrow is a publicly traded company (TSXV-MGRO) and has approximately 52.4 million common shares issued and outstanding and 59.4 million shares fully diluted.  For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

MustGrow’s Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include: those risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2024 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

Neither the TSX Venture Exchange, nor their Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.

© 2025 MustGrow Biologics Corp. All rights reserved.

Sompo to Acquire Aspen in $3.5 Billion Deal, Expanding Global Specialty Insurance and Reinsurance Reach

Posted on by slightbourne@noblecapitalmarkets.com

In a landmark move that underscores its ambition to become a dominant global insurance player, Sompo Holdings, Inc. announced it will acquire Aspen Insurance Holdings Limited for $3.5 billion. The deal, structured as an all-cash transaction at $37.50 per share, represents a 35.6 percent premium to Aspen’s unaffected share price and signals Sompo’s determination to build a diversified property and casualty (P&C) platform with international reach.

Under the agreement, all outstanding Class A ordinary shares of Aspen will be redeemed for cash, while its preference shares will remain outstanding. Once complete, Aspen will be delisted from the New York Stock Exchange. The transaction has already been unanimously approved by both companies’ boards and is expected to close in the first half of 2026, pending regulatory approvals.

For Sompo, the acquisition is more than a geographic expansion. Aspen brings over $4.6 billion in annual gross written premiums and decades of expertise across specialty insurance and reinsurance lines, including cyber risk, credit and political risk, property catastrophe, casualty reinsurance, and management liability. Its Lloyd’s syndicate provides an additional foothold in complex and high-value global markets.

Strategic acquisitions have long been a part of Sompo’s growth plan to build a robust and diversified global P&C platform, and Aspen represents a strong opportunity at the right time in the market cycle.

Beyond underwriting, Aspen also brings an alternative capital advantage. Its Aspen Capital Markets (ACM) platform, which manages more than $2 billion in assets, allows third-party investors to provide capital for reinsurance risk, generating steady management and performance fees. In 2024, 80 percent of ACM’s income came from long-tail, non-catastrophe business, making it a reliable revenue driver. For Sompo, this fee-based income will offer both diversification and a tool to better manage capital volatility.

Aspen has worked in recent years to streamline operations, reduce exposure to volatile risks, and fortify its balance sheet. With a 2024 combined ratio of 87.9 percent and an operating return on equity of 19.4 percent, the company is entering the deal on strong footing.

For Sompo, the transaction aligns with its strategic targets of achieving adjusted ROE of 13 to 15 percent and EPS growth above 12 percent by fiscal year 2026. Management expects the deal to be immediately accretive to earnings and return on equity, while delivering cost and capital synergies across the group.

As global insurance markets face mounting challenges ranging from climate risk to cyber threats, scale, diversification, and access to alternative capital are increasingly vital. With Aspen in its portfolio, Sompo is positioning itself as a global leader capable of underwriting complex risks, supporting brokers and clients, and driving long-term shareholder returns.

Release – RGP Hires Scott Rottmann as President, CFO Advisory

Posted on by aweinsoff@channelchek.com

Research News and Market Data on RGP

Aug 27, 2025

DALLAS–(BUSINESS WIRE)–RGP® (Nasdaq: RGP), a global professional services firm, today announced the appointment of Scott Rottmann to the newly created role of President, CFO Advisory.

“As finance leaders confront a future defined by data, digital innovation, and accelerated transformation, Scott’s expertise will enable us to guide clients beyond incremental improvement toward true enterprise reinvention” – Bhadresh Patel, COO, RGPShare

For more than 30 years, RGP has partnered with CFOs and their organizations to strengthen finance, accounting, risk, compliance, and tax capabilities. The creation of this dedicated leadership role formalizes and expands that commitment, positioning RGP to accelerate growth in CFO advisory, digital, technology, and data services.

Rottmann will lead RGP’s Office of the CFO consulting capability area, where the firm sees strong client demand and long-term opportunity. He will oversee the firm’s Finance & Accounting, Governance, Risk & Compliance, and Tax & Treasury practices, reporting to Chief Operating Officer Bhadresh Patel.

“Scott brings not only deep leadership experience but also the ability to help us shape the next era of CFO advisory,” said Patel. “As finance leaders confront a future defined by data, digital innovation, and accelerated transformation, Scott’s expertise will enable us to guide clients beyond incremental improvement toward true enterprise reinvention. His track record of scaling businesses, combined with his understanding of how people, process, technology, and data intersect, will help us deliver bold solutions that anticipate what CFOs need tomorrow, not just today. Scott’s addition strengthens our ability to stand alongside finance leaders as architects of resilience, growth, and long-term value creation.”

Before joining RGP, Rottmann served as a principal and partner at EY-Parthenon, where he helped CXOs, boards, and leadership teams optimize their organizations. Previously, he held senior leadership positions at Genpact and Deloitte.

“I’ve had the opportunity to lead complex, global transformation initiatives for some of the world’s most valuable brands over the past 20 years, and I’m excited to join RGP at this pivotal time of continued growth,” said Rottmann. “RGP was built on a foundation of empowering CFOs and their teams. My role is to evolve that legacy, strengthening our CFO advisory capabilities, and building even deeper, enduring partnerships within the CFO community.”

ABOUT RGP

RGP (Nasdaq: RGP) is an award-winning global professional services firm with three decades of experience helping the world’s top organizations navigate change and seize opportunity. With three integrated offerings—On-Demand Talent, Consulting, and Outsourced Services—we provide CFOs and C-suite leaders with the flexibility to solve today’s most pressing challenges on their terms, uniting strategy, execution, and talent across digital transformation, data, cloud, and global scale. Our people-first approach continues to drive innovation across industries worldwide.

Based in Dallas, Texas, with offices worldwide, we annually engage with over 1,600 clients around the world from 41 physical practice offices and multiple virtual offices. As of May 2025, RGP is proud to have served 88 percent of the Fortune 100 and has been recognized by U.S. News & World Report (2024–2025 Best Companies to Work For) and Forbes (America’s Best Management Consulting Firms 2025, America’s Best Midsize Employers 2025, World’s Best Management Consulting Firms 2024).

RGP is listed on the Nasdaq Global Select Market, the exchange’s highest tier by listing standards. To learn more about RGP, visit: http://www.rgp.com. (RGP-F)

Contacts

Investor Contact:
Jennifer Ryu, Chief Financial Officer
(US+) 1-714-430-6500
jennifer.ryu@rgp.com

Media Contact:
Pat Burek
Financial Profiles
(US+) 1-310-622-8244
pburek@finprofiles.com

Release – Conduent Announces the Successful Completion of Debt Refinancing

Posted on by aweinsoff@channelchek.com

Research News and Market Data on CNDT

August 27, 2025

Corporate

FLORHAM PARK, N.J. — Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services company, today announced it has successfully completed a refinancing of its existing term loan and revolving credit agreements.

Key Highlights of the Refinancing:

  • Full Prepayment of the Term Loan
  • Renewed Revolving Credit Facility
  • New Performance Letter of Credit Facility

Giles Goodburn, Conduent’s CFO, commented, “Completing this refinancing marks a key milestone in our strategy, further strengthening our financial foundation and positioning Conduent for future growth. This transaction provides the right mix of debt instruments to support our operations and capital allocation strategy.”

Additional details of the refinancing can be found in Conduent’s 8-K which will be filed with the U.S. Securities and Exchange Commission.

About Conduent

Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 56,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $85 billion in government payments annually, enabling 2.3 billion customer service interactions annually, empowering millions of employees through HR services every year and processing nearly 13 million tolling transactions every day. Learn more at www.conduent.com.

Note: To receive RSS news feeds, visit www.news.conduent.com. For open commentary, industry perspectives and views, visit http://twitter.com/Conduent, http://www.linkedin.com/company/conduent or http://www.facebook.com/Conduent.

Trademarks

Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

Media Contacts

Sean Collins

Conduent

Sean.Collins2@conduent.com

+1-310-497-9205

David Chen

Conduent

ir@conduent.com

Release – MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells

Posted on by aweinsoff@channelchek.com

Research News and Market Data on MAIA

August 27, 2025 9:01am EDT Download as PDF

CHICAGO, Aug. 27, 2025 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that a manuscript detailing developments in its Phase 2 THIO-101 clinical trial was accepted and published in the international peer-reviewed open access scientific journal, Cells, in a special issue, “Cellular Mechanisms of Anti-Cancer Therapies”

The manuscript, titled “Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy,” was authored by a group of oncology researchers in Turkey and the U.S. including MAIA scientists Sergei Gryaznov, Ph.D., Chief Scientific Officer and Ilgen Mender, Director of Biology Research, along with MAIA Scientific Advisory Board members Z. Gunnur Dikmen, M.D., Ph.D. and Saadettin Kiliçkap, M.D., M.Sc.

MAIA Chairman and CEO Vlad Vitoc, M.D. commented, “The importance of the findings published in Cells cannot be overstated. While conventional immunotherapies have expanded treatment options for patients, intrinsic and acquired resistance by patients remains a challenge. Our novel combination strategy of ateganosine sequenced with a checkpoint inhibitor stands out, showing encouraging results in a population with high unmet medical need.”

About Cells
Cells (ISSN 2073-4409) is an international, peer-reviewed, open access journal which provides an advanced forum for studies related to cell biology, molecular biology and biophysics. It publishes reviews, research articles, communications and technical notes. Cells is an MDPI (Multidisciplinary Digital Publishing Institute) publication.

About Ateganosine
Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

Primary Logo

Source: MAIA Biotechnology, Inc.

Released August 27, 2025

V2X (VVX) – More Potential Opportunity

Posted on by slightbourne@noblecapitalmarkets.com


Wednesday, August 27, 2025

V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Another Seat. V2X, through its Vertex Aerospace unit, was awarded a seat on the Cooperative Threat Reduction (CTR) program. CTR is a combined $3.5 billion ID/IQ multiple award vehicle, according to the Department of Defense daily awards notice. This award adds to V2X’s strong opportunity potential, in our view.

CTR. CTR is a ten-year cost-plus-fixed-fee, cost, cost-plus-award-fee, cost-plus-incentive-fee, firm-fixed-price, firm-fixed-price-level of effort, and time-and-materials contract. This contract will deliver a broad range of services and products to provide sustainable chemical, biological, radiological, and nuclear threat reduction capabilities to partner nations. The CTR Program partners with willing countries to reduce the threat from weapons of mass destruction and related materials, technologies, facilities, and expertise.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Nvidia Braces for $8 Billion Hit as China Ban and Tariffs Weigh on Earnings

Posted on by slightbourne@noblecapitalmarkets.com

Nvidia is preparing to release its second quarter earnings report, marking the final results of Big Tech’s earnings season. The announcement carries high stakes as the chipmaker navigates new challenges tied to U.S. policy shifts and strained relations with China.

The company previously warned investors that it expects an $8 billion hit to its bottom line for the quarter, primarily due to restrictions on chip sales to China. In April, former President Donald Trump imposed a ban on shipments of Nvidia’s advanced chips into China, citing national security concerns. While the ban was lifted in July, a new requirement mandates that Nvidia pay the U.S. government a 15% fee on sales to the Chinese market. This move has significantly impacted Nvidia’s projected revenue.

Adding further pressure, Trump announced plans to impose a 100% tariff on semiconductor shipments entering the United States unless companies commit to expanding domestic manufacturing. Nvidia, however, is expected to be exempt from this tariff given its existing U.S. operations and ongoing investments.

Despite these hurdles, Nvidia’s stock has continued to perform strongly throughout the year. Shares were up 35% year to date and more than 40% over the past 12 months leading into Wednesday’s report. In July, the company became the first in history to reach a $4 trillion market capitalization, a milestone that underscores its dominance in the artificial intelligence sector.

For the second quarter, Wall Street analysts expect Nvidia to post adjusted earnings per share of $1.01 on revenue of $46.2 billion, according to Bloomberg estimates. This compares with $0.68 in EPS and $30 billion in revenue during the same quarter last year, representing year-over-year growth of nearly 50%. While this growth rate is lower than the triple-digit surges Nvidia reported last year during the height of the AI boom, analysts believe the slowdown could be temporary.

Evercore ISI analyst Mark Lipacis suggested that a leveling out around 50% growth may attract new momentum investors and lead to further valuation expansion. Meanwhile, Nvidia’s data center business, the backbone of its AI strategy, is projected to generate $41.2 billion in sales this quarter, up sharply from $26.2 billion a year ago. Gaming, its second largest division, is expected to contribute $3.8 billion.

Investors will be listening closely to management’s commentary on shipments of Nvidia’s GB200 super chip, the rollout of its Blackwell Ultra processors, and the company’s position in China. Some analysts caution that third quarter guidance could come in below expectations if Nvidia excludes direct revenue from China sales.

At the same time, Nvidia faces political headwinds abroad. The Chinese government has warned local companies to avoid using Nvidia’s products, citing alleged security risks, a claim the company denies. Nvidia has signaled its willingness to cooperate with regulators and is reportedly preparing a new chip design tailored for the Chinese market, though it will need U.S. government approval before any shipments can begin.

As Nvidia heads into its earnings release, the company sits at the center of the global debate over technology, trade, and national security. The results will not only reflect Nvidia’s financial strength but also provide clues about how it intends to balance growth with the mounting pressures of geopolitics.

Keurig Dr Pepper to Acquire JDE Peet’s, Creating Two Distinct Beverage Giants

Posted on by slightbourne@noblecapitalmarkets.com

Keurig Dr Pepper announced plans to acquire European coffee powerhouse JDE Peet’s in a landmark $18 billion all-cash deal, signaling a major reshaping of the company’s portfolio. Once finalized, the transaction will split the business into two separate entities: a coffee-focused company combining Keurig’s single-serve pods with JDE Peet’s global coffee brands, and a soft drink company housing iconic beverages such as Dr Pepper, Snapple, and 7UP.

The deal is being framed as a strategic response to shifting consumer trends and mounting pressures in the coffee market. While the beverage segment has remained strong, Keurig Dr Pepper’s coffee business has faced challenges in recent years due to rising coffee bean prices, supply disruptions, and competition from store brands. By separating the two businesses, the company aims to allow each entity to pursue tailored growth strategies suited to their respective markets.

The new coffee company, projected to generate around $16 billion in annual sales, will be headquartered in Burlington, Massachusetts, with international operations managed from Amsterdam. Meanwhile, the beverage business, with roughly $11 billion in annual sales, will operate out of Frisco, Texas. This structural shift allows both companies to focus on specialized operational efficiencies and innovation. Keurig Dr Pepper executives expect that the coffee-focused entity will be better equipped to navigate global commodity pressures, including droughts in major coffee-exporting regions like Brazil and Vietnam, as well as newly imposed U.S. tariffs on Brazilian coffee imports.

JDE Peet’s brings nearly 50 coffee and tea brands from around the world, including France’s L’Or, Germany’s Jacobs coffee, and New Zealand’s Ti Ora tea. The company has demonstrated strong pricing power, with first-half sales rising nearly 20% to just under $6 billion, driven primarily by strategic price increases. Keurig Dr Pepper anticipates leveraging JDE Peet’s international reach and brand diversity to accelerate innovation and expand global market share.

In contrast, Keurig Dr Pepper’s soft drink division has outperformed in recent quarters, with sales rising 10.5% year-over-year to $2.7 billion, fueled by strong demand for flavored beverages. By keeping this segment distinct, management aims to maintain focus on profitable core brands while continuing to pursue growth in emerging beverage trends.

Industry analysts view the transaction as part of a broader trend among major food and beverage companies to realign portfolios. Similar moves in recent years include Kellogg’s spin-off of its snack brands and the acquisition activity by Mars and Ferrero, highlighting the increasing importance of market specialization in maintaining competitiveness.

The deal is expected to close in the first half of 2026, pending shareholder and regulatory approvals. Management changes are also slated: Timothy Cofer, CEO of Keurig Dr Pepper, will lead the beverage business, while CFO Sudhanshu Priyadarshi will oversee the newly formed coffee company. Executives emphasize that the separation will create two highly focused, growth-oriented companies, each with the agility to respond to consumer demand and evolving market conditions.

As consumer habits continue to evolve and commodity prices fluctuate, the split positions Keurig Dr Pepper to optimize value across both the coffee and soft drink markets, potentially unlocking growth and operational efficiencies that were harder to achieve under a unified structure.

Intel Deal Sparks Talk of Government Stakes in Defense Firms — Could Small-Cap Contractors Be the Next Beneficiaries?

Posted on by slightbourne@noblecapitalmarkets.com

The U.S. government’s surprise move to take a nearly 10% stake in Intel has raised fresh questions about whether similar investments could be directed toward defense contractors. Commerce Secretary Howard Lutnick signaled this week that defense remains a central area of discussion, citing its deep ties to government funding and its strategic importance to national security.

The comments sent shares of major defense primes such as Lockheed Martin and Northrop Grumman higher, underscoring how sensitive the sector is to policy developments. But beyond the established giants, investors are now weighing whether small-cap defense firms could become the next beneficiaries of heightened federal interest.

Unlike the household names of the defense world, many smaller contractors play critical yet less visible roles in the military supply chain. These firms often specialize in advanced components, niche technologies, cybersecurity solutions, or unmanned systems. With Washington openly considering how to finance munitions acquisitions and strengthen industrial capacity, smaller players could find themselves on stronger footing.

For small-cap stocks, the potential upside comes from two angles. First, government scrutiny of prime contractors could create opportunities for subcontractors to capture a greater share of defense budgets. If policy shifts encourage more competition in procurement, companies developing next-generation drones, satellite systems, or precision components could see contracts flow their way. Second, direct or indirect investment by the U.S. could help shore up balance sheets and provide access to growth capital that is often scarce in the sector.

The Intel deal also signals a broader shift in Washington’s approach to industrial policy. By taking an equity stake rather than simply providing subsidies, the government aligned its financial interests with a major company’s success. If similar mechanisms are applied in defense, even at smaller scales, it could transform the risk–reward profile for publicly traded small-cap contractors. Investors would be betting not just on execution, but on the implicit backing of federal policy.

Still, risks remain. The defense sector is highly regulated, and the prospect of deeper government involvement raises questions about oversight and shareholder rights. The Intel deal gave the U.S. no board seat or governance role, but uncertainty lingers over how similar arrangements might play out in defense. Additionally, defense budgets are subject to political cycles, making small-cap firms vulnerable to swings in appropriations and shifting strategic priorities.

Market reaction to Lutnick’s remarks illustrates how policy talk alone can move stocks, but investors should be cautious about reading too much into early signals. Large primes like Lockheed Martin remain deeply entrenched as key suppliers, and any structural changes would take time to ripple through the industry. For smaller contractors, however, the current environment could present a rare window of opportunity.

If the government follows through on exploring new financing models for defense, small-cap stocks could benefit disproportionately, gaining visibility, liquidity, and growth momentum. For investors willing to tolerate the volatility, Lutnick’s comments may have opened the door to a new chapter in defense-sector investing—one where the biggest opportunities lie not only with the giants, but with the up-and-coming firms that keep the supply chain moving.

Release – Bitcoin Depot Taps Fintech Executive Alex Holmes for Board of Directors

Posted on by aweinsoff@channelchek.com

Research News and Market Data on BTM

August 26, 2025 8:00 AM EDT Download as PDF

Former MoneyGram Chairman and CEO Brings Two Decades of Payments and Compliance Expertise

ATLANTA, Aug. 26, 2025 (GLOBE NEWSWIRE) — Bitcoin Depot (NASDAQ: BTM), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, today announced the appointment of Alex Holmes to its Board of Directors and Audit Committee, effective August 20, 2025. Holmes is a globally recognized leader in payments, compliance, and blockchain innovation, with more than 25 years of experience guiding financial services companies through transformation, regulatory complexity, and global expansion. As a member of Bitcoin Depot’s Board and Audit Committee, Holmes will provide strategic guidance as the crypto industry continues to rapidly evolve.

“Alex has a proven track record of scaling financial services companies while maintaining the highest standards of compliance and consumer trust. His expertise will be critical in helping to guide Bitcoin Depot’s next phase of growth,” said Brandon Mintz, CEO and founder of Bitcoin Depot. “As we continue to expand our footprint, set new industry standards of compliance, and expand crypto access for customers across North America and beyond, we couldn’t be more thrilled to welcome Alex on board.”

Holmes currently serves as Executive Vice Chairman of United Texas Bank, a strategic advisor to several Web3 ventures including Orobit Inc., and a board member of Jingle Pay / Acamas Group in Dubai. He previously spent nearly two decades at MoneyGram International, where he served as Chairman and CEO from 2016-2025. During his tenure, Holmes led MoneyGram’s transformation into a global fintech powerhouse, expanding digital adoption, modernizing compliance infrastructure, and pioneering cross-border blockchain integration initiatives. Under his leadership, MoneyGram earned recognition as one of the Best Places to Work, Most Trustworthy Companies in America, and a Top Workplace (2022–2025). He also oversaw the company’s $2 billion acquisition by Madison Dearborn Partners in 2023.

“Bitcoin Depot has built a unique and powerful platform at the intersection of cash and crypto, with a sustained focus on accessibility, consumer value, and compliance,” said Holmes. “I look forward to supporting Bitcoin Depot as it continues to strengthen its leadership in the BTM sector and advances its mission to bring crypto to the masses.”

For more information, visit www.bitcoindepot.com.

About Bitcoin Depot 
Bitcoin Depot Inc. (Nasdaq: BTM) was founded in 2016 with the mission to connect those who prefer to use cash to the broader, digital financial system. Bitcoin Depot provides its users with simple, efficient and intuitive means of converting cash into Bitcoin, which users can deploy in the payments, spending and investing space. Users can convert cash to bitcoin at Bitcoin Depot kiosks in 47 states and at thousands of name-brand retail locations in 31 states through its BDCheckout product. The Company has the largest market share in North America with over 9,000 kiosk locations as of June 2025. Learn more at www.bitcoindepot.com.

Cautionary Note Regarding Forward-Looking Statements
This press release and any oral statements made in connection herewith include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. Forward-looking statements are any statements other than statements of historical fact, and include, but are not limited to, statements regarding the expectations of plans, business strategies, objectives and growth and anticipated financial and operational performance, including our growth strategy and ability to increase deployment of our products and services, the anticipated effects of the Amendment, and the closing of the Preferred Sale. These forward-looking statements are based on management’s current beliefs, based on currently available information, as to the outcome and timing of future events. Forward-looking statements are often identified by words such as “anticipate,” “appears,” “approximately,” “believe,” “continue,” “could,” “designed,” “effect,” “estimate,” “evaluate,” “expect,” “forecast,” “goal,” “initiative,” “intend,” “may,” “objective,” “outlook,” “plan,” “potential,” “priorities,” “project,” “pursue,” “seek,” “should,” “target,” “when,” “will,” “would,” or the negative of any of those words or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. In making these statements, we rely upon assumptions and analysis based on our experience and perception of historical trends, current conditions, and expected future developments, as well as other factors we consider appropriate under the circumstances. We believe these judgments are reasonable, but these statements are not guarantees of any future events or financial results. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control.

These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; failure to realize the anticipated benefits of the business combination; future global, regional or local economic and market conditions; the development, effects and enforcement of laws and regulations; our ability to manage future growth; our ability to develop new products and services, bring them to market in a timely manner and make enhancements to our platform; the effects of competition on our future business; our ability to issue equity or equity-linked securities; the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries; and those factors described or referenced in filings with the Securities and Exchange Commission. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that we do not presently know or that we currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect our expectations, plans or forecasts of future events and views as of the date of this press release. We anticipate that subsequent events and developments will cause our assessments to change.

We caution readers not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other factors that affect the subject of these statements, except where we are expressly required to do so by law. All written and oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary statement.

Contacts: 

Investors
Cody Slach
Gateway Group, Inc.
949-574-3860
BTM@gateway-grp.com 

Media
Brenlyn Motlagh, Ryan Deloney
Gateway Group, Inc. 
949-574-3860
BTM@gateway-grp.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bb9b7b43-f0dd-4b84-ab0e-1d999431d046

Primary Logo
Alex Holmes
Bitcoin Depot Taps Fintech Executive Alex Holmes for Board of Directors

Source: Bitcoin Depot Inc.

Released August 26, 2025

The GEO Group (GEO) – Some Estate Planning Moves

Posted on by slightbourne@noblecapitalmarkets.com


Tuesday, August 26, 2025

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 103 facilities totaling approximately 83,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 18,000 employees.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Stock Sales. After the market closed yesterday, The GEO Group Executive Chairman George Zoley filed a Form 4 with the Securities and Exchange Commission reporting the sale of GEO shares. We would note the sales were in connection with pre-arranged estate planning that ultimately will result in the sale of 230,918 GEO shares held by Mr. Zoley or trusts held for the benefit of his children.

Details. According to the filing, a total of 72,038 GEO shares were sold on 8/21 and 8/25 at prices ranging from $21.16-$21.72 per share. An additional 75,000 shares were reported sold for estate planning purposes on a Form 4 filed August 20th, with these shares sold at prices ranging from $20.93-$21.72 per share.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Great Lakes Dredge & Dock (GLDD) – Some Additional Work & Delivery of the Amelia Island

Posted on by slightbourne@noblecapitalmarkets.com


Tuesday, August 26, 2025

Great Lakes Dredge & Dock Corporation is the largest provider of dredging services in the United States. In addition, Great Lakes is fully engaged in expanding its core business into the rapidly developing offshore wind energy industry. The Company has a long history of performing significant international projects. The Company employs experienced civil, ocean and mechanical engineering staff in its estimating, production and project management functions. In its over 131-year history, the Company has never failed to complete a marine project. Great Lakes owns and operates the largest and most diverse fleet in the U.S. dredging industry, comprised of approximately 200 specialized vessels. Great Lakes has a disciplined training program for engineers that ensures experienced-based performance as they advance through Company operations. The Company’s Incident-and Injury-Free® (IIF®) safety management program is integrated into all aspects of the Company’s culture. The Company’s commitment to the IIF® culture promotes a work environment where employee safety is paramount.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Some Additional Work. According to the daily Department of Defense contract awards notice, Great Lakes continues to receive additional work, adding to an already full scorecard. The recent contract wins highlight the strength of the Company, as well as the overall bid environment, in our view.

Amelia Island. Last week, Great Lakes announced the delivery of its newest Jones Act-compliant hopper dredge, the Amelia Island. This completes the Company’s dredge newbuild program. The Amelia Island is specially designed for efficient and safe operations along shallow and narrow waters throughout all U.S. coastlines. With a full schedule for 2025 and 2026, the dredge will be going immediately to work.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Euroseas (ESEA) – Two New Vessels to be Delivered in 2028

Posted on by slightbourne@noblecapitalmarkets.com


Tuesday, August 26, 2025

Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 140 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA. Euroseas operates in the container shipping market. Euroseas’ operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Two new orders. Euroseas Ltd. executed a contract for the construction of two modern fuel-efficient 4,300 twenty-foot-equivalent unit container vessels that are expected to be delivered in March and May of 2028. The vessels will cost approximately $59.25 million each and will be financed with a combination of debt and equity. Currently, Euroseas has a fleet of 22 vessels, including 15 feeder containerships and seven intermediate containerships, with a cargo capacity of 67,494 twenty-foot equivalent units (TEU). After the sale of the M/V Marcos V and the delivery of four intermediate containerships in 2027 and 2028, Euroseas’ fleet will consist of 25 vessels with a total carrying capacity of 78,344 TEU.

Commitment to growth and modernization. The most recent orders demonstrate Euroseas’ commitment to growing and modernizing its fleet. Management believes that investing in eco intermediate-sized containerships, a segment with a low orderbook and an aging existing fleet, will enhance the company’s competitive position, enable it to capitalize on future market opportunities, and create value for shareholders. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.